Emyria (ASX:EMD) has announced leadership changes designed to position it to meet anticipated growth in demand for its unique care programs and new forms of therapy.
The company is developing and delivering new treatments for mental health and select neurological conditions.
Greg Hutchinson, Emyria’s current non-executive chair, will assume the role of executive chairman.
Dr Michael Winlo, Emyria’s CEO and managing director, will transition into the new chief scientific officer role, reporting to the executive chairman. Dr Winlo will oversee Emyria’s real-world evidence research, clinical trials, and proprietary drug discovery programs.
As executive chairman, Mr Hutchinson will drive Emyria’s expansion as the company prepares for significant growth off the back of encouraging clinical results from its innovative mental health programs, which include MDMA-assisted therapy for PTSD and psilocybin-assisted therapy for treatment-resistant depression.
Mr Hutchinson said, “Emyria is uniquely positioned to transform mental health care in Australia as well as other global jurisdictions. I look forward to positioning the Company for growth, and drive expansion of its exceptional clinical services to meet the rising demand for better mental health interventions. I would like to thank Dr Michael Winlo for his 5 years of service as Managing Director and CEO of Emyria."
Dr Winlo added, "2025 is set to be a transformative year for Emyria driven by Mr Hutchinson’s expertise growing clinical services and our expanding engagement with payers. I am excited to continue supporting the Company by dedicating my energy, skills and experience to Emyria’s critical research and discovery programs. Our growing body of real-world evidence will play a pivotal role in refining our unique approach to mental health treatments and scaling access to those who need them most."